About Prexton Therapeutics
Prexton Therapeutics is a Healthcare company based in Plan-les-ouates (Switzerland) founded in 2012, and was acquired by Lundbeck in March 2018. Parkinsons drugs targeting mGluR3 and mGluR4 receptors are developed. Prexton Therapeutics has raised $43.46 million across 3 funding rounds from investors including Lundbeck, Forbion and Seroba Lifesciences. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative.
Company details
Prexton Therapeutics was founded in 2012 and operates in the biotechnology sector, focusing on treatments for Parkinsons disease. Metabotropic glutamate receptors mGluR3 and mGluR4 are targeted through the development of positive allosteric modulators to enhance mGluR4 activity. These receptors interact with glutamate, an excitatory neurotransmitter linked to functions such as learning, memory, anxiety, and pain perception. Motor behaviors in Parkinsons patients are expected to be restored by this approach.
- Headquarters Plan-les-ouates, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website prextontherapeutics.com
- Social LinkedIn
- Acquired by Lundbeck (Mar 2018)
Funding Insights of Prexton Therapeutics
Prexton Therapeutics has successfully raised a total of $43.46M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $31 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $43.46M
- Total Rounds 3
- Last Round Series B — $31M
- First Round $2.59M
(Jul 2012)
- Investors Count 5
All 3 funding rounds of Prexton Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2017 | $31M | Series B | – | – | |
| Feb 2015 | $9.87M | Series A | – | – | |
| Jul 2012 | $2.59M | Seed | – | – |
6 investors in total: 6 institutional.
Investors in Prexton Therapeutics
Prexton Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Lundbeck, Forbion and Seroba Lifesciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Ysios Capital is recognized as a leading life sciences investor. | ysioscapital.com | Barcelona, Spain | ||
Investments are made by Sunstone in early-stage European companies. | sunstone.eu | Copenhagen, Denmark | ||
Venture capital firm investing in multiple sectors | m-ventures.com | Amsterdam, Netherlands | ||
Seroba Lifesciences is focused on life sciences venture capital investments. | seroba-lifesciences.com | Dublin, Ireland | ||
Drugs for CNS disorders are developed and advanced. | 1915 | lundbeck.com | Copenhagen, Denmark |
Investor details for Prexton Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Prexton Therapeutics
4 dated milestones of Prexton Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Prexton Therapeutics is founded.
- Funding First funding round of $2.6M.
- Funding Latest funding round, Series B, of $31.0M.
- Exit Acquired by Lundbeck.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prexton Therapeutics
Complete news archive for Prexton Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prexton Therapeutics
Prexton Therapeutics was founded in 2012.
Prexton Therapeutics is headquartered in Plan-les-ouates, Switzerland. It is registered at Plan-les-ouates, Geneva, Switzerland.
Prexton Therapeutics is a funded company, having raised a total of $43.46M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.59M, raised on Jul 2012.
Prexton Therapeutics was founded in 2012 and operates in the biotechnology sector, focusing on treatments for Parkinsons disease. Metabotropic glutamate receptors mGluR3 and mGluR4 are targeted through the development of positive allosteric modulators to enhance mGluR4 activity. These receptors interact with glutamate, an excitatory neurotransmitter linked to functions such as learning, memory, anxiety, and pain perception. Motor behaviors in Parkinsons patients are expected to be restored by this approach.
Prexton Therapeutics has 6 investors. Key investors include Lundbeck, Forbion, Seroba Lifesciences, Ysios Capital, and Sunstone.
Yes. Prexton Therapeutics was acquired by Lundbeck in March 2018.